November 17, 2016
Revance management is scheduled to participate in a fireside chat
discussion on
Interested parties can access the live audio webcast for both of these conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replay will be available after the conclusion of the live presentation for approximately 30 days.
About
Revance, a
The company's lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis and has the potential to be the first long-acting neurotoxin. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. More information on Revance may be found at www.revance.com.
"
View source version on businesswire.com: http://www.businesswire.com/news/home/20161117005815/en/
Investors:
jherbert@revance.com
or
abavishi@burnsmc.com
or
Trade
Media:
Nadine Tosk, (504) 453-8344
nadinepr@gmail.com
Source:
News Provided by Acquire Media